Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415778 | 0.88 | PLA2G2A (0.37) | MAPTARHTTGAAALDH1A1 | |
| SCHEMBL12415766 | 0.86 | MAPT (0.45) | MAPTARMEN1KMT2AHTT | |
| SCHEMBL12415771 | 0.84 | POLB (0.46) | MAPTARMEN1KMT2AHTT | |
| SCHEMBL691743 | 0.82 | KMT2A (0.41) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL12415769 | 0.82 | MAPT (0.43) | MAPTARMEN1KMT2AHTT | |
| SCHEMBL10206823 | 0.81 | MAPT (0.44) | MAPTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL2791412 | 0.80 | CYP2C19 (0.43) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL12953758 | 0.79 | POLB (0.40) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL12569062 | 0.79 | NPSR1 (0.41) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL13051455 | 0.78 | L3MBTL1 (0.46) | MAPTMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | MAPT 2120/4885AR 401/4885MEN1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.